The FDA has approved the use of PD-1/PD-L1 inhibitors in combination with CTLA-4 antibodies for the treatment of NSCLC, which represents an opportunity and a challenge for specialists to more thoroughly understand the irAEs induced by the two ICIs in combination. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.